Panna Sharma - Lantern Pharma CEO President
| LTRN Stock | USD 3.11 0.04 1.30% |
CEO
Panna Sharma is CEO President of Lantern Pharma
| Age | 53 |
| Address | 1920 McKinney Avenue, Dallas, TX, United States, 75201 |
| Phone | 972 277 1136 |
| Web | https://www.lanternpharma.com |
Lantern Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2807) % which means that it has lost $0.2807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4482) %, meaning that it created substantial loss on money invested by shareholders. Lantern Pharma's management efficiency ratios could be used to measure how well Lantern Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Lantern Pharma's Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Non Currrent Assets Other is likely to grow to about 47.8 K, while Total Assets are likely to drop about 36.4 M.Similar Executives
| Found 7 records | CEO Age | ||
| Daniel Pinto | JPMorgan Chase Co | 61 | |
| Mary Erdoes | JPMorgan Chase Co | 57 | |
| Jennifer Piepszak | JPMorgan Chase Co | 53 | |
| Marianne Lake | JPMorgan Chase Co | 54 | |
| Satya Nadella | Microsoft | 57 | |
| Douglas Petno | JPMorgan Chase Co | 55 | |
| Alan Schnitzer | The Travelers Companies | 58 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 |
Lantern Pharma Leadership Team
Elected by the shareholders, the Lantern Pharma's board of directors comprises two types of representatives: Lantern Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lantern. The board's role is to monitor Lantern Pharma's management team and ensure that shareholders' interests are well served. Lantern Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lantern Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DVM MS, CoFounder Advisor | ||
| Nicole Leber, Finance Associate | ||
| MS BS, Head Operations | ||
| Kishor Bhatia, Chief Consultant | ||
| Marc MD, Chief Therapeutics | ||
| Panna Sharma, CEO President | ||
| David Margrave, CFO Secretary |
Lantern Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lantern Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 5.37 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Shares Owned By Insiders | 14.74 % | ||||
| Shares Owned By Institutions | 24.10 % | ||||
| Number Of Shares Shorted | 165.56 K | ||||
| Price To Book | 1.25 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) |
Pair Trading with Lantern Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Lantern Stock
| 0.64 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.71 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lantern Stock
| 0.7 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.56 | PHVS | Pharvaris BV | PairCorr |
| 0.49 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.46 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.37 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.
The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.